Cargando…

Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Sclair, Seth N, Little, Ester, Levy, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816277/
https://www.ncbi.nlm.nih.gov/pubmed/26312413
http://dx.doi.org/10.1038/ctg.2015.33
_version_ 1782424683531993088
author Sclair, Seth N
Little, Ester
Levy, Cynthia
author_facet Sclair, Seth N
Little, Ester
Levy, Cynthia
author_sort Sclair, Seth N
collection PubMed
description Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress regardless of treatment. Bilirubin <1.0 and alkaline phosphatase <2.0 x the upper limit of normal at 1 year after treatment appear to predict 10-year survival. Ursodeoxycholic acid (UDCA) is the recommended treatment for PBC, and recent studies with obeticholic acid showed promising results for UDCA non-responders. Unlike PBC, no therapy has been shown to alter the natural history of PSC. The recommended initial diagnostic test for PSC is magnetic resonance cholangiopancreatography, typically showing bile duct wall thickening, focal bile duct dilatation, and saccular dilatation of the intra- and/or extrahepatic bile ducts. Immunoglobulin 4-associated cholangitis must be excluded when considering the diagnosis of PSC, to allow for proper treatment, and monitoring of disease progression. In addition to the lack of therapy, PSC is a pre-malignant condition and close surveillance is indicated.
format Online
Article
Text
id pubmed-4816277
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48162772016-04-13 Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis Sclair, Seth N Little, Ester Levy, Cynthia Clin Transl Gastroenterol Clinical/Narrative Review Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, cholestatic diseases of the liver with common clinical manifestations. Early diagnosis and treatment of PBC slows progression and decreases the need for transplant. However, one-third of patients will progress regardless of treatment. Bilirubin <1.0 and alkaline phosphatase <2.0 x the upper limit of normal at 1 year after treatment appear to predict 10-year survival. Ursodeoxycholic acid (UDCA) is the recommended treatment for PBC, and recent studies with obeticholic acid showed promising results for UDCA non-responders. Unlike PBC, no therapy has been shown to alter the natural history of PSC. The recommended initial diagnostic test for PSC is magnetic resonance cholangiopancreatography, typically showing bile duct wall thickening, focal bile duct dilatation, and saccular dilatation of the intra- and/or extrahepatic bile ducts. Immunoglobulin 4-associated cholangitis must be excluded when considering the diagnosis of PSC, to allow for proper treatment, and monitoring of disease progression. In addition to the lack of therapy, PSC is a pre-malignant condition and close surveillance is indicated. Nature Publishing Group 2015-08 2015-08-27 /pmc/articles/PMC4816277/ /pubmed/26312413 http://dx.doi.org/10.1038/ctg.2015.33 Text en Copyright © 2015 American College of Gastroenterology http://creativecommons.org/licenses/by-nc-nd/4.0/ Clinical and Translational Gastroenterology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Clinical/Narrative Review
Sclair, Seth N
Little, Ester
Levy, Cynthia
Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title_full Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title_fullStr Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title_full_unstemmed Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title_short Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
title_sort current concepts in primary biliary cirrhosis and primary sclerosing cholangitis
topic Clinical/Narrative Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816277/
https://www.ncbi.nlm.nih.gov/pubmed/26312413
http://dx.doi.org/10.1038/ctg.2015.33
work_keys_str_mv AT sclairsethn currentconceptsinprimarybiliarycirrhosisandprimarysclerosingcholangitis
AT littleester currentconceptsinprimarybiliarycirrhosisandprimarysclerosingcholangitis
AT levycynthia currentconceptsinprimarybiliarycirrhosisandprimarysclerosingcholangitis